Increased R&D investment to support growth
First written in FY2018-Q1. 22 of 33 entries say "Softened", first in FY2018-Q2. Latest entry: 2026-07-30.
Media Links moved to the "Worse" side of this theme in 2018, 7 years before the typical company in this theme (2025).
3 other companies' latest entry also says "Softened".
- 2026-07-30SoftenedEarnings
「R&D expenses decreased from ¥175.752 million to ¥163.605 million.」
While the Company is pursuing measures to improve R&D efficiency, R&D expenses declined from the same period of the previous year. - FY2026SoftenedAnnual report
「As a result, total R&D expenses for the consolidated fiscal year were ¥678 million.」
Although development of Xscend® continued, R&D expenses were ¥678 million, down from ¥707 million in the previous fiscal year. A reduction was evident in actual R&D investment. - FY2026-H1AdvancedAnnual report
「R&D expenses for the six months ended the second quarter were ¥354 million, up 1.1% year on year.」
R&D expenses were ¥354 million, up 1.1% year on year, shifting to a slight increase from the decline in the first half of the previous fiscal year. It was stated that there had been no material change in the status of research and development activities themselves. - FY2025RestatedAnnual report
「To that end, we will continue to invest in research and development.」
The policy of continuing R&D investment has been maintained, and R&D expenses were ¥707 million. No significant change in direction from ¥702,968 thousand in the previous fiscal year was stated. - FY2025-H1SoftenedAnnual report
「R&D expenses for the six months ended the second quarter were ¥350 million, down 1.6% year on year.」
While it was stated that there had been no material change in research and development activities, actual investment decreased after the period of increases through the previous fiscal year. - FY2024-Q3AdvancedAnnual report
「R&D expenses for the nine months ended the third quarter were ¥528 million, up 85.4% year on year.」
R&D expenses were ¥528 million, up 85.4% year on year, and R&D investment is shifting to a substantial increase from the reduction recorded for the previous full fiscal year. - FY2024-Q2AdvancedAnnual report
「R&D expenses for the six months ended the second quarter were ¥355 million, up 76.0% year on year.」
R&D expenses were ¥355 million, up 76.0% year on year, and R&D investment shifted to a substantial increase in the first half from the reduction recorded for the previous full fiscal year. - FY2024-Q1AdvancedAnnual report
「R&D expenses for the three months ended the first quarter were ¥170 million, up 71.3% year on year.」
R&D expenses were ¥170 million, up 71.3% year on year, and R&D investment shifted to a substantial quarterly increase from the reduction recorded for the previous full fiscal year. - FY2023SoftenedAnnual report
「As a result, total R&D expenses for the consolidated fiscal year were ¥455 million.」
Although the company developed Xscend®, R&D expenses were ¥455 million, down 40.0% year on year, and actual investment decreased from the increase in the previous fiscal year. - FY2023-Q3SoftenedAnnual report
「R&D expenses for the nine months ended the third quarter were ¥285 million, down 48.7% year on year.」
While it was stated that there had been no material change in the status of research and development activities, R&D expenses were ¥285 million, down 48.7% year on year, and actual investment decreased over the nine months after turning to an increase in the previous fiscal year. - FY2023-Q2SoftenedAnnual report
「R&D expenses for the six months ended the second quarter were ¥202 million, down 45.5% year on year.」
While it was stated that there had been no material change in the status of research and development activities, R&D expenses were ¥202 million, down 45.5% year on year, and actual investment decreased in the first half after turning to an increase in the previous fiscal year. - FY2023-Q1SoftenedAnnual report
「R&D expenses for the three months ended the first quarter were ¥99 million, down 42.9% year on year.」
While it was stated that there had been no material change in research and development activities themselves, R&D expenses decreased 42.9% year on year, representing a reduction in actual R&D investment after the increase in the previous fiscal year. - FY2022AdvancedAnnual report
「R&D expenses were ¥758 million, up 21.4% year on year. This was due to an increase in R&D expenses for new products.」
R&D expenses were ¥758 million, up 21.4% year on year due to new product development, shifting to an increase from the downward trend through the previous fiscal year. - FY2022-Q3AdvancedAnnual report
「R&D expenses were ¥555 million, up 22.8% year on year.」
R&D expenses to support growth were ¥555 million, up 22.8% year on year, and R&D investment shifted to an increase after having declined year on year. - FY2022-Q2AdvancedAnnual report
「In terms of expenses, selling, general and administrative expenses rose to ¥999 million, up 15.1% year on year, mainly because research and development expenses aimed at further growth increased to ¥371 million, up 24.4%.」
R&D expenses aimed at further growth were ¥371 million, up 24.4% year on year, indicating a specific increase in R&D investment from the same period of the previous year. - FY2022-Q1AdvancedAnnual report
「In terms of expenses, selling, general and administrative expenses were ¥484 million, up 13.2% year on year, mainly because R&D expenses to pursue further growth were increased to ¥174 million, up 18.8% year on year.」
R&D expenses aimed at further growth were ¥174 million, up 18.8% year on year, indicating an increase in R&D investment on a quarterly basis. - FY2021SoftenedAnnual report
「However, R&D expenses of ¥624 million for securing future profits were maintained at approximately the same level as in the previous consolidated fiscal year, despite being down 5.6% year on year.」
Although research and development activities are continuing, R&D expenses were ¥624 million, down 5.6% year on year, representing a reduction from the previous fiscal year rather than an increase. - FY2021-Q3SoftenedAnnual report
「R&D expenses were ¥452 million, down 2.2% year on year.」
Although research and development activities are continuing, R&D expenses decreased 2.2% year on year, and the reduction in actual R&D investment to support growth is continuing. - FY2021-Q2SoftenedAnnual report
「R&D expenses were ¥298 million, down 0.1% year on year, remaining at approximately the same level as the previous year.」
Although research and development activities are continuing, R&D expenses decreased 0.1% year on year, shifting to a flat level from the increase seen in the previous quarter. - FY2021-Q1AdvancedAnnual report
「R&D expenses for the three months ended the first quarter were ¥147 million, up 3.8% year on year.」
R&D expenses were ¥147 million, up 3.8% year on year, marking an increase on a quarterly basis after the downward trend that had continued through the previous fiscal year. It was stated that there had been no material change in the status of research and development activities themselves. - FY2020-Q3SoftenedAnnual report
「R&D expenses for the nine months ended the third quarter were ¥462 million, down 8.2% year on year.」
Although research and development activities are continuing, R&D expenses were ¥462 million, down 8.2% year on year, and the reduction in actual R&D investment to support growth is continuing. - FY2020-Q2SoftenedAnnual report
「R&D expenses were ¥298 million, down 11.7% year on year.」
Although research and development activities are continuing, R&D expenses decreased 11.7% year on year, representing a reduction in actual R&D investment to support growth. - FY2020-Q1SoftenedAnnual report
「R&D expenses were ¥141 million, down 17.3% year on year.」
Although research and development activities are continuing, R&D expenses were ¥141 million, down 17.3% year on year, representing a reduction in actual R&D investment to support growth. - FY2019SoftenedAnnual report
「R&D expenses were ¥668 million, down 35.7% year on year.」
Although research and development of new and next-generation products is continuing, R&D expenses decreased 35.7% year on year, and the reduction in actual investment to support growth is continuing. - FY2019-Q3SoftenedAnnual report
「R&D expenses were ¥504 million, down 36.9% year on year.」
Although research and development activities are continuing, R&D expenses were ¥504 million, down 36.9% year on year, and the reduction in actual R&D investment to support growth is continuing. - FY2019-Q2SoftenedAnnual report
「R&D expenses were ¥338 million, down 40.1% year on year.」
Although research and development activities are continuing, R&D expenses were ¥338 million, down 40.1% year on year, and the reduction in actual R&D investment to support growth is continuing. - FY2019-Q1SoftenedAnnual report
「(4) Research and Development Activities R&D expenses for the three months ended the first quarter were ¥171 million, down 40.1% year on year.」
Although research and development activities are continuing, R&D expenses were ¥171 million, down 40.1% year on year, representing a further reduction from the downward trend in the previous full fiscal year. - FY2018SoftenedAnnual report
「R&D expenses were ¥1,038 million, down 16.9% year on year.」
Although research and development of new and next-generation products is continuing, R&D expenses decreased 16.9% year on year, representing a reduction in actual investment to support growth. - FY2018-Q3SoftenedAnnual report
「R&D expenses for the nine months ended the third quarter were ¥798 million, down 10.4% year on year.」
R&D expenses were ¥798 million, down 10.4% year on year, and, following the previous quarter, no actual increase in R&D investment to support growth was evident, indicating a weakening of the policy to increase spending. - FY2018-Q2SoftenedAnnual report
「R&D expenses were ¥564 million, down 3.6% year on year.」
Although an increase in R&D expenses had been indicated in the previous quarter, R&D expenses decreased 3.6% year on year in the six months ended the second quarter, indicating weaker execution of the policy to increase spending. - FY2018-Q1First statedAnnual report
「To pursue further growth amid intensifying competition, R&D expenses will be increased to ¥285 million, up 10.4% year on year.」
The company has specified a measure to increase R&D expenses to ¥285 million, up 10.4% year on year, to address intensifying competition and support growth.